| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.4 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.16 | 0.4 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.4 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.052 | 0.4 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.4 |